“Solutions for Heart Disease: The Science of the Future Today”
Doris A. Taylor, PhD, FAHA, FACC;
Director, Regenerative Medicine Research, Texas Heart Institute at St. Luke’s Episcopal Hospital
Tuesday, November 8, 2012
5:45 p.m. – Networking Reception
6:30 p.m. – Presentation
Technologies that involve cardiovascular tissue engineering present a promising approach by which replacement tissues and even organs can be developed at the bench and, ultimately, delivered to the patient when other treatments have failed or as improved reparative strategies. For organs that may not repair themselves and require a transplant, a whole human heart made from a patient’s own cells and tissues could be on the immediate horizon. Technology being developed right now in Texas could help make this possible.
Recent advances in cell biology and scaffold technology have made the “engineering” of complex tissues, organs, and even organ systems feasible. Dr. Taylor is working to “engineer” cardiac muscle, valves, and vasculature, with many of these technologies now progressing to first-in-human use trials.
In this talk, Dr. Taylor will discuss the discovery and application of new knowledge to improve patient care and to prevent cardiovascular disease. Dr. Taylor will share how building new cell and organ based solutions for severe diseases could impact millions of patients suffering or who are at risk for these diseases.
Dr. Doris A. Taylor is the Director of Regenerative Medicine Research at the Texas Heart Institute (THI). Before joining THI, Dr. Taylor directed the Center for Cardiovascular Repair at the University of Minnesota. She also held academic appointments as the Medtronic Bakken Chair, Professor of Integrative Biology and Physiology and Professor of Medicine at UMN and an adjunct position as Professor of Medicine at Duke. Dr. Taylor came to the University of Minnesota from Duke University Medical School, where she was Associate Professor in the Department of Medicine, Division of Cardiology and Associate Professor, Department of Biomedical Engineering.
She received her Ph.D. in Pharmacology from The University of Texas Southwestern Medical Center and did her postdoctoral training in Molecular Biology at Albert Einstein College of Medicine, Bronx, New York.
Among other research responsibilities, Dr. Taylor is currently on the advisory board to the International Society for Heart & Lung Transplantation (ISHLT) Basic Science/Translational Research Council and is on the scientific committee and jury of the Grand Prix Lefoulon-Delalande Foundation at the Institut de France, which awards a half-million euro prize yearly to a scientist with the greatest impact on the treatment of cardiovascular disease. She serves on numerous advisory and review panels nationally and internationally and on several editorial boards.